Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Escalating Single Doses of PF-05230907 (Recombinant Factor Xa Variant FXa I16L ) Are Safe and Demonstrate Hemostatic Pharmacology in Healthy Volunteers

Steven Arkin, MD, Fei Hua, PhD, Constantino Kantaridis, MD, Gang Li, PhD, Dana Parsons-Rich, MPH, MPA, Debra D Pittman

Blood (2016) 128 (22): 3781.

https://doi.org/10.1182/blood.V128.22.3781.3781

Published: 2016

Journal Articles

A Quantitative Systems Pharmacology Model for the Coagulation Network Describes Biomarker Changes Observed in a Clinical Study with FXa Variant and Predicts Age-Associated Biomarker Variations

Satyaprakash Nayak, PhD, Dooyoung Lee, PhD, Steven Arkin, MD, Steven W. Martin, PhD, Anne C. Heatherington, PhD, William S. Denney, PhD, Paolo Vicini, PhD, Fei Hua, PhD

Blood (2015) 126 (23): 3502.

https://doi.org/10.1182/blood.V126.23.3502.3502

Published: 2015

Journal Articles

Evaluation of Potential Safety Biomarkers for Monitoring Thrombogenic Potential of FXa I16L

Michael Bolt, PhD DABT, Fei Hua, PhD, Karrie Brenneman, DVM, PhD DACVP, John Graves, MT, MA, Steven Arkin, MD, Kay Criswell

Blood (2014) 124 (21): 4237.

https://doi.org/10.1182/blood.V124.21.4237.4237

Published: 2014

Journal Articles

A Systems Biology Model for the Coagulation Network in Non-Bleeding State Describes Baseline Activity of Coagulation

Dooyoung Lee, PhD, Satyaprakash Nayak, PhD, Debra Pittman, Steven Arkin, MD, Steven Martin, PhD, Anne C Heatherington, PhD, Paolo Vicini, PhD, Fei Hua, PhD

Blood (2014) 124 (21): 4238.

https://doi.org/10.1182/blood.V124.21.4238.4238

Published: 2014

Journal Articles

Evidence for a protective role of Mcl-1 in proteasome inhibitor-induced apoptosis

Alessio Nencioni, Fei Hua, Christopher P. Dillon, Rayka Yokoo, Christoph Scheiermann, Mike H. Cardone, Eleonora Barbieri, Ilaria Rocco, Anna Garuti, Sebastian Wesselborg, Claus Belka, Peter Brossart, Franco Patrone, Alberto Ballestrero

Blood (2005) 105 (8): 3255–3262.

https://doi.org/10.1182/blood-2004-10-3984

Published: 2005

NARROW

Escalating Single Doses of PF-05230907 (Recombinant Factor Xa Variant FXa I16L ) Are Safe and Demonstrate Hemostatic Pharmacology in Healthy Volunteers

A Quantitative Systems Pharmacology Model for the Coagulation Network Describes Biomarker Changes Observed in a Clinical Study with FXa Variant and Predicts Age-Associated Biomarker Variations

Evaluation of Potential Safety Biomarkers for Monitoring Thrombogenic Potential of FXa I16L

A Systems Biology Model for the Coagulation Network in Non-Bleeding State Describes Baseline Activity of Coagulation

Evidence for a protective role of Mcl-1 in proteasome inhibitor-induced apoptosis

Email alerts

ASH Publications

American Society of Hematology

Escalating Single Doses of PF-05230907 (Recombinant Factor Xa Variant FXa I16L ) Are Safe and Demonstrate Hemostatic Pharmacology in Healthy Volunteers

A Quantitative Systems Pharmacology Model for the Coagulation Network Describes Biomarker Changes Observed in a Clinical Study with FXa Variant and Predicts Age-Associated Biomarker Variations

Evaluation of Potential Safety Biomarkers for Monitoring Thrombogenic Potential of FXa I16L

A Systems Biology Model for the Coagulation Network in Non-Bleeding State Describes Baseline Activity of Coagulation

Evidence for a protective role of Mcl-1 in proteasome inhibitor-induced apoptosis

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only